129:@0.890196:0.957873:0.914726:0.957873:0.914726:0.938882:0.890196:0.938882:0.007346:0.008593:0.008591
5:@0.941813:0.435294:0.963291:0.435294:0.963291:0.387816:0.941813:0.387816:0.021478
OPTIMIZING NANOPORE SEQUENCING-BASED DETECTION OF STRUCTURAL VARIANTS ENABLES:@0.340931:0.057372:0.882352:0.057372:0.882352:0.040253:0.340931:0.040253:0.008442:0.007975:0.006387:0.003511:0.011112:0.003511:0.006630:0.003511:0.008759:0.008404:0.002988:0.008759:0.007919:0.008759:0.008442:0.008050:0.008442:0.008423:0.006985:0.002988:0.007807:0.006985:0.008442:0.008367:0.006985:0.008759:0.008255:0.003511:0.008759:0.008404:0.005155:0.008121:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.006985:0.006387:0.006985:0.008178:0.006387:0.003511:0.008442:0.008759:0.002988:0.008442:0.006593:0.002988:0.007732:0.006387:0.008367:0.008367:0.008180:0.006387:0.008367:0.008423:0.007919:0.006292:0.002801:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.006313:0.007807:0.002988:0.006985:0.008759:0.007919:0.008236:0.006481:0.006871:0.007807
INDIVIDUALIZED CIRCULATING TUMOR DNA-BASED DISEASE MONITORING IN CANCER PATIENTS:@0.337347:0.073247:0.882352:0.073247:0.882352:0.056128:0.337347:0.056128:0.003511:0.008759:0.008423:0.003511:0.007620:0.003511:0.008423:0.008253:0.007919:0.006481:0.003511:0.006630:0.006985:0.008423:0.002988:0.008255:0.003511:0.008309:0.008255:0.008367:0.006481:0.007097:0.006387:0.003511:0.008759:0.008404:0.002988:0.006387:0.008367:0.011112:0.008442:0.008423:0.002988:0.008423:0.008759:0.007543:0.005155:0.008124:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.003511:0.007807:0.006985:0.007713:0.007807:0.006985:0.002988:0.011112:0.008442:0.008759:0.003511:0.006311:0.008442:0.008423:0.003511:0.008759:0.008404:0.002988:0.003511:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.007581:0.007099:0.006387:0.003511:0.006985:0.008759:0.006311:0.007807
put can be decreased even further to as little as 80 ng when using flow cells with increased :@0.147059:0.121273:0.886555:0.121273:0.886555:0.100900:0.147059:0.100900:0.011048:0.011071:0.006437:0.003356:0.009108:0.009085:0.011756:0.003356:0.011254:0.009039:0.003356:0.011322:0.009108:0.008994:0.007442:0.009291:0.009291:0.007875:0.009108:0.011391:0.003356:0.009336:0.009633:0.009039:0.011756:0.003356:0.006369:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.003356:0.006211:0.011048:0.003356:0.009291:0.007670:0.003356:0.005250:0.005273:0.006163:0.006620:0.005182:0.009039:0.003356:0.009291:0.007670:0.003356:0.010432:0.010432:0.003356:0.011459:0.009861:0.003356:0.014792:0.011299:0.009039:0.011756:0.003356:0.011413:0.007601:0.005615:0.011459:0.009861:0.003356:0.005638:0.005570:0.010866:0.014723:0.003356:0.008994:0.008948:0.005387:0.005250:0.007670:0.003356:0.014723:0.005273:0.006617:0.011459:0.003356:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009108:0.011391:0.004109
sensitivity for DNA (research prototype flow cells provided by ONT). :@0.147059:0.141852:0.731146:0.141852:0.731146:0.121479:0.147059:0.121479:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.004109:0.006024:0.010843:0.007807:0.004109:0.015773:0.015408:0.014929:0.004109:0.006939:0.007442:0.009039:0.007875:0.009291:0.009085:0.007442:0.008765:0.011459:0.004109:0.011071:0.007442:0.010820:0.006209:0.010820:0.006437:0.009724:0.011505:0.009039:0.004109:0.005638:0.005567:0.010866:0.014723:0.004109:0.008994:0.008948:0.005387:0.005250:0.007670:0.004109:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009108:0.011391:0.004109:0.010843:0.009724:0.004109:0.016047:0.016230:0.013240:0.006939:0.004497:0.004109
Long-read sequencing is an excellent method for the detection of SVs at nucleotide :@0.147059:0.162431:0.886462:0.162431:0.886462:0.142058:0.147059:0.142058:0.011824:0.010843:0.011459:0.009861:0.007533:0.007442:0.009291:0.009291:0.011391:0.007487:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.007487:0.005615:0.007670:0.007487:0.009085:0.011756:0.007487:0.009106:0.009884:0.008994:0.008948:0.005387:0.005182:0.009039:0.011391:0.006437:0.007487:0.017488:0.009128:0.006620:0.011302:0.011274:0.011391:0.007487:0.006026:0.010843:0.007807:0.007487:0.006620:0.011302:0.009039:0.007487:0.011322:0.009128:0.006211:0.009106:0.009108:0.006437:0.005547:0.010843:0.011756:0.007487:0.010843:0.006209:0.007487:0.010112:0.015089:0.007670:0.007487:0.008811:0.006437:0.007487:0.011391:0.011347:0.008765:0.005182:0.009106:0.010822:0.006437:0.005547:0.011322:0.009039:0.004109
resolution, even at low sequencing depth, because each long-read that bridges a break-:@0.147059:0.183009:0.882353:0.183009:0.882353:0.162636:0.147059:0.162636:0.007442:0.009039:0.007875:0.010934:0.004908:0.011071:0.006437:0.005547:0.010843:0.011756:0.004497:0.005182:0.009336:0.009633:0.009039:0.011756:0.005182:0.008811:0.006437:0.005182:0.005182:0.010866:0.014723:0.005182:0.007875:0.009108:0.010703:0.011347:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005182:0.011322:0.009131:0.011048:0.006620:0.011459:0.004497:0.005182:0.011254:0.009108:0.009106:0.008813:0.011413:0.007873:0.009039:0.005182:0.009288:0.009291:0.008765:0.011459:0.005182:0.005182:0.010843:0.011459:0.009861:0.007533:0.007442:0.009291:0.009291:0.011391:0.005182:0.006620:0.011391:0.008811:0.006437:0.005182:0.010820:0.007807:0.005547:0.011391:0.009656:0.009039:0.007670:0.005182:0.009291:0.005182:0.010820:0.007442:0.009291:0.009402:0.010642:0.007533
point-junction provides direct information on the breakpoint position and sequence  . :@0.147059:0.203588:0.886461:0.203588:0.886461:0.183215:0.147059:0.183215:0.011505:0.010843:0.005615:0.011391:0.006437:0.007533:0.004953:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011756:0.004040:0.011069:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.007670:0.004040:0.011391:0.005615:0.007442:0.009108:0.009108:0.006437:0.004040:0.005615:0.011756:0.006024:0.010843:0.007807:0.017577:0.008813:0.006437:0.005547:0.010843:0.011756:0.004040:0.010843:0.011756:0.004040:0.006620:0.011299:0.009039:0.004040:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.004040:0.011502:0.010957:0.007601:0.005273:0.006437:0.005547:0.010843:0.011756:0.004040:0.009085:0.011598:0.011391:0.004040:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009039:0.004109:0.018170:0.004497:0.004109
204:@0.859611:0.195972:0.877856:0.195972:0.877856:0.184095:0.859611:0.184095:0.006082:0.006082:0.006082
Sequencing of a tumor sample on a single GridION/MinION nanopore flow cell gen-:@0.147059:0.224167:0.882353:0.224167:0.882353:0.203794:0.147059:0.203794:0.010592:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005730:0.010843:0.006209:0.005730:0.009291:0.005730:0.006163:0.011413:0.017485:0.010843:0.007807:0.005730:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.005730:0.010843:0.011756:0.005730:0.009291:0.005730:0.007601:0.005615:0.011459:0.009930:0.005182:0.009039:0.005730:0.015477:0.007807:0.005547:0.011391:0.006825:0.016047:0.016230:0.007099:0.019423:0.005615:0.011756:0.006825:0.016047:0.016230:0.005730:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.005730:0.005638:0.005570:0.010866:0.014723:0.005730:0.008994:0.008948:0.005387:0.005250:0.005730:0.009656:0.009039:0.011824:0.007533
erates insufficient sequencing data to accurately establish a complete genomic profile. :@0.147059:0.244745:0.886393:0.244745:0.886393:0.224373:0.147059:0.224373:0.009039:0.007898:0.008811:0.006209:0.009039:0.007670:0.006460:0.005615:0.011619:0.007510:0.011413:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.006460:0.007875:0.009108:0.010703:0.011347:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.006460:0.011571:0.008813:0.006549:0.009291:0.006460:0.006209:0.011048:0.006460:0.009291:0.008994:0.009108:0.011413:0.007898:0.008811:0.006209:0.008948:0.005182:0.009724:0.006460:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.006460:0.009291:0.006460:0.008994:0.010843:0.017280:0.011162:0.005182:0.009131:0.006209:0.009039:0.006460:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.006460:0.011071:0.007442:0.010843:0.005684:0.005821:0.005182:0.008743:0.004497:0.004109
However, using the pipeline developed here, we efficiently enriched for patient-specific :@0.147059:0.265324:0.886505:0.265324:0.886505:0.244951:0.147059:0.244951:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.005045:0.011413:0.007601:0.005615:0.011459:0.009861:0.005045:0.006620:0.011299:0.009039:0.005045:0.011071:0.005273:0.011505:0.008948:0.005250:0.005615:0.011596:0.009039:0.005045:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011502:0.009108:0.011391:0.005045:0.011302:0.009039:0.007442:0.008743:0.004497:0.005045:0.014518:0.009039:0.005045:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006617:0.005184:0.009724:0.005045:0.009039:0.011756:0.007807:0.005547:0.008765:0.011299:0.009106:0.011391:0.005045:0.006029:0.010840:0.007807:0.005045:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004109
somatic SV events - irrespective of their functional impact on tumor biology. Despite the :@0.147059:0.285903:0.886551:0.285903:0.886551:0.265530:0.147059:0.265530:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.003607:0.010112:0.015089:0.003607:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.003607:0.007533:0.003607:0.005615:0.007807:0.007439:0.009039:0.007512:0.011502:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.003607:0.010843:0.006209:0.003607:0.006620:0.011299:0.009039:0.005615:0.007807:0.003607:0.006369:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.003607:0.005615:0.017280:0.011368:0.009291:0.009106:0.006437:0.003607:0.010843:0.011756:0.003607:0.006166:0.011413:0.017485:0.010843:0.007807:0.003607:0.010820:0.005545:0.010934:0.005184:0.011048:0.010544:0.007989:0.004497:0.003607:0.016230:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.003607:0.006620:0.011299:0.009039:0.004109
very low coverage, the computational method functions independently of correspond-:@0.147059:0.306482:0.882353:0.306482:0.882353:0.286109:0.147059:0.286109:0.009633:0.009039:0.008400:0.009724:0.005113:0.005182:0.010866:0.014723:0.005113:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.008743:0.004497:0.005113:0.006620:0.011299:0.009039:0.005113:0.008994:0.010843:0.017280:0.011048:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.005113:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.005113:0.006366:0.011413:0.011598:0.009108:0.006437:0.005545:0.010843:0.011619:0.007670:0.005113:0.005615:0.011596:0.011322:0.009128:0.011505:0.009039:0.011596:0.011322:0.009039:0.011391:0.006620:0.005182:0.009724:0.005113:0.010843:0.006209:0.005113:0.008994:0.010843:0.007807:0.007442:0.009039:0.007510:0.011505:0.010843:0.011596:0.011416:0.007533
ing germline sequencing data. These assets make our pipeline a cost-efficient assay for :@0.147059:0.327060:0.886507:0.327060:0.886507:0.306687:0.147059:0.306687:0.005615:0.011459:0.009861:0.005730:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.005730:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005730:0.011573:0.008811:0.006549:0.009291:0.004497:0.005730:0.011470:0.011311:0.009039:0.007875:0.009039:0.005730:0.009291:0.007533:0.007875:0.009131:0.006437:0.007670:0.005730:0.017577:0.009405:0.010272:0.009039:0.005730:0.010820:0.011413:0.007807:0.005730:0.011071:0.005273:0.011505:0.008948:0.005250:0.005615:0.011596:0.009039:0.005730:0.009291:0.005730:0.008994:0.010957:0.007512:0.006437:0.007533:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.005730:0.009291:0.007533:0.007944:0.008925:0.009724:0.005730:0.006026:0.010843:0.007807:0.004109
detection of personalized somatic SV biomarkers. Furthermore, on average 50% of the :@0.147059:0.347639:0.886514:0.347639:0.886514:0.327266:0.147059:0.327266:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.005364:0.010843:0.006209:0.005364:0.011505:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005615:0.008834:0.009108:0.011391:0.005364:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005364:0.010112:0.015089:0.005364:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.004497:0.005364:0.010731:0.011413:0.007964:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008745:0.004497:0.005364:0.010843:0.011756:0.005364:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.005364:0.010432:0.010432:0.015043:0.005364:0.010845:0.006209:0.005364:0.006620:0.011299:0.009039:0.004109
detected SVs are somatic, which minimizes the hands-on effort needed for validation :@0.147059:0.368218:0.886459:0.368218:0.886459:0.347845:0.147059:0.347845:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009108:0.011391:0.006150:0.010112:0.015089:0.007670:0.006152:0.009085:0.007442:0.009039:0.006152:0.007873:0.010845:0.017577:0.008809:0.006437:0.005547:0.008994:0.004497:0.006152:0.014792:0.011459:0.005547:0.008765:0.011459:0.006150:0.017645:0.005615:0.011756:0.005615:0.017645:0.005615:0.008834:0.009039:0.007670:0.006150:0.006622:0.011299:0.009039:0.006150:0.011391:0.009087:0.011596:0.011391:0.007670:0.007533:0.010840:0.011756:0.006152:0.009039:0.005969:0.005787:0.010843:0.007967:0.006437:0.006150:0.011598:0.009106:0.009108:0.011322:0.009108:0.011391:0.006152:0.006026:0.010843:0.007807:0.006150:0.009838:0.009402:0.005250:0.005547:0.011573:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109
purposes. For all analyzed tumors, we identified at least five somatic SV biomarkers per :@0.147059:0.388796:0.886507:0.388796:0.886507:0.368423:0.147059:0.368423:0.011048:0.011413:0.007967:0.011505:0.010957:0.007873:0.009039:0.007670:0.004497:0.004657:0.010683:0.010843:0.007807:0.004657:0.009405:0.005387:0.005250:0.004657:0.009087:0.011687:0.009405:0.005182:0.009724:0.008834:0.009106:0.011391:0.004657:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004497:0.004657:0.014518:0.009039:0.004657:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.004657:0.008811:0.006437:0.004657:0.005182:0.009291:0.009291:0.007510:0.006437:0.004657:0.005684:0.005615:0.009633:0.009039:0.004657:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004657:0.010112:0.015089:0.004657:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.004657:0.011505:0.009039:0.007807:0.004109
patient, an amount within the range of biomarkers used to trace ctDNA in previous :@0.147059:0.409375:0.886510:0.409375:0.886510:0.389002:0.147059:0.389002:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.006985:0.009085:0.011756:0.006985:0.009085:0.017485:0.010820:0.011413:0.011391:0.006437:0.006985:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.006985:0.006620:0.011299:0.009039:0.006985:0.007896:0.009085:0.011461:0.009656:0.009039:0.006985:0.010843:0.006209:0.006985:0.010820:0.005547:0.010845:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.006985:0.011413:0.007875:0.009108:0.011391:0.006985:0.006209:0.011048:0.006985:0.006437:0.007896:0.009291:0.008994:0.009039:0.006985:0.009108:0.006437:0.015773:0.015408:0.014929:0.006985:0.005615:0.011756:0.006985:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.004109
work:@0.147059:0.429954:0.190544:0.429954:0.190544:0.409581:0.147059:0.409581:0.014518:0.010843:0.007601:0.010523
69,166,362:@0.190544:0.422338:0.244441:0.422338:0.244441:0.410460:0.190544:0.410460:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. With expected increases in sequencing throughput from ONT sequencing, :@0.244439:0.429954:0.886418:0.429954:0.886418:0.409581:0.244439:0.409581:0.004497:0.004383:0.019951:0.005273:0.006620:0.011459:0.004383:0.009108:0.010089:0.011505:0.009108:0.009108:0.006209:0.009108:0.011391:0.004383:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009039:0.007670:0.004383:0.005615:0.011756:0.004383:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004383:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011094:0.011048:0.011071:0.006437:0.004383:0.006412:0.007442:0.010843:0.017645:0.004383:0.016047:0.016230:0.013354:0.004383:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009679:0.004497:0.004109
the performance of the pipeline will improve significantly. Furthermore, the use of cheap :@0.147059:0.450532:0.886368:0.450532:0.886368:0.430160:0.147059:0.430160:0.006620:0.011299:0.009039:0.003607:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017577:0.009085:0.011596:0.008994:0.009039:0.003607:0.010843:0.006209:0.003607:0.006620:0.011299:0.009039:0.003607:0.011071:0.005273:0.011505:0.008948:0.005250:0.005615:0.011596:0.009039:0.003607:0.014723:0.005750:0.005387:0.005250:0.003607:0.005615:0.017278:0.011071:0.007442:0.010866:0.009633:0.009039:0.003607:0.007601:0.005615:0.009861:0.011756:0.005615:0.005684:0.005613:0.009108:0.009087:0.011391:0.006620:0.005182:0.007989:0.004497:0.003607:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.003607:0.006620:0.011299:0.009039:0.003607:0.011413:0.007875:0.009039:0.003607:0.010843:0.006209:0.003607:0.008765:0.011302:0.009288:0.008811:0.011276:0.004109
disposable flow cells (Flongle) could reduce assay costs to  /  of the current sequencing :@0.147059:0.471111:0.886426:0.471111:0.886426:0.450738:0.147059:0.450738:0.011391:0.005615:0.007510:0.011505:0.010957:0.007944:0.009108:0.010911:0.005182:0.009039:0.005205:0.005638:0.005570:0.010866:0.014723:0.005205:0.008994:0.008948:0.005387:0.005250:0.007670:0.005205:0.006939:0.011139:0.005182:0.010843:0.011459:0.009930:0.005182:0.009039:0.006939:0.005205:0.008994:0.010820:0.011550:0.005182:0.011391:0.005205:0.007442:0.009108:0.011048:0.011345:0.008994:0.009039:0.005205:0.009291:0.007533:0.007944:0.008925:0.009724:0.005205:0.008994:0.010957:0.007510:0.006437:0.007670:0.005205:0.006209:0.011048:0.004109:0.007257:0.007099:0.006081:0.005205:0.010843:0.006209:0.005205:0.006620:0.011299:0.009039:0.005205:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005205:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.005615:0.011459:0.009861:0.004109
1:@0.639991:0.464965:0.646073:0.464965:0.646073:0.453088:0.639991:0.453088:0.006082
5:@0.653172:0.468384:0.659254:0.468384:0.659254:0.456507:0.653172:0.456507:0.006082
price of 800€  . The minimal costs of this assay would enable the broader application of :@0.147059:0.491690:0.886433:0.491690:0.886433:0.471317:0.147059:0.471317:0.011071:0.007807:0.005547:0.008994:0.009039:0.003972:0.010843:0.006209:0.003972:0.010432:0.010432:0.010432:0.010432:0.004109:0.018114:0.004497:0.003972:0.011470:0.011311:0.009039:0.003972:0.017645:0.005615:0.011756:0.005615:0.017577:0.009405:0.005250:0.003972:0.008994:0.010957:0.007510:0.006437:0.007670:0.003972:0.010843:0.006209:0.003972:0.006620:0.011459:0.005615:0.007670:0.003972:0.009291:0.007533:0.007944:0.008925:0.009724:0.003972:0.014518:0.010820:0.011550:0.005182:0.011391:0.003972:0.009039:0.011690:0.009108:0.010911:0.005182:0.009039:0.003972:0.006620:0.011299:0.009039:0.003972:0.010820:0.007442:0.011139:0.009291:0.011322:0.009039:0.007807:0.003972:0.008811:0.011048:0.011162:0.005250:0.005547:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.003972:0.010843:0.006209:0.004109
363:@0.260218:0.484074:0.278463:0.484074:0.278463:0.472196:0.260218:0.472196:0.006082:0.006082:0.006082
such individualized SV monitoring in cancer patients.:@0.147059:0.512269:0.599116:0.512269:0.599116:0.491896:0.147059:0.491896:0.007510:0.011345:0.008765:0.011459:0.004109:0.005615:0.011596:0.011391:0.005547:0.009838:0.005547:0.011048:0.011596:0.009405:0.005250:0.005615:0.008834:0.009106:0.011391:0.004109:0.010112:0.015089:0.004109:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009861:0.004109:0.005615:0.011756:0.004109:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004109:0.011365:0.008813:0.006437:0.005545:0.009039:0.011391:0.006437:0.007670:0.004497
We retrospectively traced levels of ctDNA with two SVs per patient for four prostate can-:@0.147059:0.532847:0.882353:0.532847:0.882353:0.512474:0.147059:0.512474:0.018649:0.009039:0.003538:0.007442:0.009131:0.006437:0.007442:0.010957:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.008948:0.005182:0.009724:0.003538:0.006437:0.007898:0.009291:0.008994:0.009108:0.011391:0.003538:0.005182:0.009336:0.009633:0.008948:0.005250:0.007670:0.003538:0.010843:0.006209:0.003538:0.009108:0.006437:0.015773:0.015406:0.014929:0.003538:0.014723:0.005273:0.006617:0.011459:0.003538:0.006437:0.014518:0.011048:0.003538:0.010112:0.015089:0.007670:0.003538:0.011505:0.009039:0.007807:0.003538:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003538:0.006026:0.010843:0.007807:0.003538:0.006026:0.010820:0.011413:0.007807:0.003538:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.003538:0.009108:0.009085:0.011735:0.007533
cer patients and compared tumor dynamics to clinical biomarkers such as PSA and ALP. :@0.147059:0.553426:0.886462:0.553426:0.886462:0.533053:0.147059:0.533053:0.008994:0.009039:0.007807:0.003892:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.003892:0.009085:0.011596:0.011391:0.003892:0.008994:0.010843:0.017280:0.011368:0.009085:0.007442:0.009108:0.011391:0.003890:0.006163:0.011413:0.017485:0.010843:0.007807:0.003892:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.003890:0.006211:0.011048:0.003890:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.003890:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.003892:0.007510:0.011345:0.008765:0.011459:0.003892:0.009291:0.007670:0.003890:0.012167:0.010112:0.014929:0.003892:0.009085:0.011596:0.011391:0.003890:0.014929:0.011619:0.008811:0.004497:0.004109
The quantitative measurement of SVs in ctDNA suggests that VAFs of SVs correlate with :@0.147059:0.574005:0.886484:0.574005:0.886484:0.553632:0.147059:0.553632:0.011470:0.011311:0.009039:0.003675:0.010706:0.011596:0.009085:0.011391:0.006437:0.005273:0.006551:0.008811:0.006437:0.005547:0.009633:0.009039:0.003675:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.017485:0.009039:0.011391:0.006437:0.003675:0.010843:0.006209:0.003675:0.010112:0.015089:0.007670:0.003675:0.005615:0.011756:0.003675:0.009108:0.006437:0.015773:0.015408:0.014929:0.003675:0.007510:0.011413:0.009975:0.009656:0.009039:0.007510:0.006437:0.007670:0.003675:0.006620:0.011391:0.008811:0.006437:0.003675:0.012578:0.014929:0.011276:0.007670:0.003675:0.010843:0.006209:0.003675:0.010112:0.015089:0.007670:0.003675:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006209:0.009039:0.003675:0.014723:0.005271:0.006620:0.011459:0.004109
tumor load (Pros1 and Pros5). Moreover, the SVs would have indicated progression of :@0.147059:0.594583:0.886373:0.594583:0.886373:0.574210:0.147059:0.574210:0.006163:0.011413:0.017485:0.010843:0.007807:0.005273:0.005182:0.011139:0.009291:0.011391:0.005273:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.005273:0.009085:0.011596:0.011391:0.005273:0.011916:0.007442:0.010957:0.007670:0.010432:0.006939:0.004497:0.005273:0.018969:0.010843:0.007442:0.009108:0.010866:0.009633:0.009039:0.006255:0.004497:0.005273:0.006620:0.011299:0.009039:0.005273:0.010112:0.015089:0.007670:0.005273:0.014518:0.010820:0.011550:0.005182:0.011391:0.005273:0.011391:0.008925:0.009633:0.009039:0.005273:0.005615:0.011596:0.011391:0.005547:0.009108:0.008811:0.006209:0.009108:0.011391:0.005273:0.011071:0.007442:0.011048:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.005273:0.010843:0.006209:0.004109
disease earlier than PSA did in some patients (Pros1 and Pros 4). Even though we only :@0.147059:0.615162:0.886421:0.615162:0.886421:0.594789:0.147059:0.594789:0.011391:0.005615:0.007875:0.009291:0.009291:0.007873:0.009039:0.005022:0.009291:0.009085:0.007601:0.005250:0.005547:0.009039:0.007807:0.005022:0.006620:0.011391:0.009085:0.011756:0.005022:0.012167:0.010112:0.014929:0.005022:0.011391:0.005547:0.011391:0.005022:0.005615:0.011756:0.005022:0.007875:0.010843:0.017485:0.009039:0.005022:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005022:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.005022:0.009085:0.011598:0.011391:0.005022:0.011916:0.007442:0.010957:0.007670:0.005022:0.010432:0.006939:0.004497:0.005022:0.011804:0.009633:0.009039:0.011756:0.005022:0.006620:0.011299:0.010820:0.011413:0.009930:0.011459:0.005022:0.014518:0.009039:0.005022:0.010843:0.011870:0.005182:0.009724:0.004109
tested two SVs per patient, this clearly illustrates the potential clinical utility of quanti-:@0.147059:0.635741:0.882353:0.635741:0.882353:0.615368:0.147059:0.615368:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.005307:0.006437:0.014518:0.011048:0.005305:0.010112:0.015089:0.007670:0.005307:0.011505:0.009039:0.007807:0.005307:0.011365:0.008813:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.005305:0.006620:0.011459:0.005615:0.007670:0.005307:0.008765:0.005182:0.009291:0.009085:0.007601:0.005182:0.009724:0.005307:0.005750:0.005387:0.004908:0.011413:0.007512:0.006437:0.007896:0.008811:0.006211:0.009039:0.007670:0.005305:0.006620:0.011299:0.009039:0.005307:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.005305:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.005307:0.011071:0.006437:0.005752:0.005250:0.005271:0.006437:0.009724:0.005307:0.010843:0.006209:0.005307:0.010706:0.011596:0.009085:0.011391:0.006437:0.005613:0.007533
fying ctDNA with SVs to monitor response to treatment. The assay could be optimized :@0.147059:0.656319:0.886391:0.656319:0.886391:0.635947:0.147059:0.635947:0.006506:0.009724:0.005615:0.011459:0.009861:0.004816:0.009108:0.006437:0.015773:0.015408:0.014929:0.004816:0.014723:0.005273:0.006620:0.011459:0.004816:0.010112:0.015089:0.007670:0.004816:0.006209:0.011048:0.004816:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.004816:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004816:0.006209:0.011048:0.004816:0.006437:0.007442:0.009288:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.004816:0.011470:0.011311:0.009039:0.004816:0.009291:0.007533:0.007944:0.008925:0.009724:0.004816:0.008994:0.010820:0.011550:0.005182:0.011391:0.004816:0.011251:0.009039:0.004816:0.010820:0.011048:0.006437:0.005615:0.017645:0.005615:0.008834:0.009108:0.011391:0.004109
by not only identifying the tumor-specific SVs, but also SVs that represent the dominant :@0.147059:0.676898:0.886457:0.676898:0.886457:0.656525:0.147059:0.656525:0.010843:0.009724:0.003835:0.011596:0.010820:0.006437:0.003835:0.010843:0.011870:0.005182:0.009724:0.003835:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006503:0.009724:0.005615:0.011459:0.009861:0.003835:0.006620:0.011299:0.009039:0.003835:0.006163:0.011413:0.017485:0.010845:0.007234:0.007533:0.007512:0.011502:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.003835:0.010112:0.015089:0.007670:0.004497:0.003835:0.010797:0.011069:0.006437:0.003835:0.009402:0.005250:0.007875:0.011048:0.003835:0.010112:0.015089:0.007670:0.003835:0.006620:0.011391:0.008811:0.006437:0.003835:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.003835:0.006620:0.011299:0.009039:0.003835:0.011322:0.010843:0.017645:0.005615:0.011687:0.009085:0.011391:0.006437:0.004109
disease clone and upcoming, targetable subclones. In addition, larger prospective studies :@0.147059:0.697477:0.886393:0.697477:0.886393:0.677104:0.147059:0.677104:0.011391:0.005615:0.007875:0.009291:0.009291:0.007873:0.009039:0.003584:0.008765:0.005182:0.010843:0.011596:0.009039:0.003584:0.009085:0.011598:0.011391:0.003584:0.011071:0.011502:0.008994:0.010843:0.017645:0.005615:0.011459:0.009679:0.004497:0.003584:0.006551:0.009085:0.007624:0.009656:0.009131:0.006551:0.009108:0.010911:0.005182:0.009039:0.003584:0.007510:0.011345:0.011254:0.008765:0.005182:0.010843:0.011596:0.009039:0.007670:0.004497:0.003584:0.006894:0.011756:0.003584:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011756:0.004497:0.003584:0.005433:0.009085:0.007624:0.009656:0.009039:0.007807:0.003584:0.011071:0.007442:0.010957:0.007510:0.011502:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.003584:0.007510:0.006163:0.011347:0.011391:0.005547:0.009039:0.007670:0.004109
should confirm that indeed measuring SVs improves clinical decision making in patients :@0.147059:0.718056:0.886516:0.718056:0.886516:0.697683:0.147059:0.697683:0.007556:0.011299:0.010820:0.011550:0.005182:0.011391:0.003310:0.008994:0.010843:0.011756:0.005684:0.005684:0.007807:0.017645:0.003298:0.006620:0.011391:0.008811:0.006437:0.003310:0.005615:0.011596:0.011322:0.009108:0.009106:0.011391:0.003310:0.017485:0.009291:0.009291:0.007510:0.011413:0.007807:0.005615:0.011459:0.009861:0.003298:0.010112:0.015089:0.007670:0.003310:0.005615:0.017280:0.011069:0.007444:0.010866:0.009633:0.009039:0.007670:0.003298:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.003298:0.011322:0.009108:0.008994:0.005615:0.007601:0.005547:0.010843:0.011756:0.003310:0.017577:0.009405:0.010703:0.005615:0.011459:0.009861:0.003310:0.005615:0.011756:0.003298:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004109
with metastatic prostate, and other cancer types.:@0.147059:0.738634:0.550040:0.738634:0.550040:0.718261:0.147059:0.718261:0.014723:0.005273:0.006620:0.011459:0.004109:0.017485:0.009131:0.006551:0.009291:0.007510:0.006549:0.008811:0.006437:0.005547:0.008994:0.004109:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.008743:0.004497:0.004109:0.009085:0.011596:0.011391:0.004109:0.010820:0.006620:0.011299:0.009039:0.007807:0.004109:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004109:0.006437:0.009724:0.011505:0.009039:0.007670:0.004497
Conclusions:@0.147059:0.803353:0.279944:0.803353:0.279944:0.775242:0.147059:0.775242:0.012841:0.013132:0.013626:0.012841:0.010168:0.013015:0.012144:0.006217:0.013132:0.013626:0.012144
Clinicians are well aware of the dynamic response of cancer to treatment but lack the :@0.147059:0.845203:0.886327:0.845203:0.886327:0.824830:0.147059:0.824830:0.014746:0.005250:0.005615:0.011756:0.005547:0.008994:0.005796:0.009085:0.011621:0.007670:0.006095:0.009085:0.007442:0.009039:0.006095:0.014518:0.008948:0.005387:0.005250:0.006095:0.008925:0.014723:0.009085:0.007442:0.009039:0.006095:0.010840:0.006209:0.006095:0.006617:0.011302:0.009039:0.006095:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.006095:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006095:0.010843:0.006209:0.006095:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.006095:0.006211:0.011048:0.006095:0.006437:0.007442:0.009288:0.008813:0.006437:0.017485:0.009039:0.011391:0.006437:0.006095:0.010797:0.011071:0.006437:0.006095:0.005433:0.009291:0.008765:0.010523:0.006095:0.006620:0.011299:0.009039:0.004109
tools to monitor these changes in real-time and thus generally respond to alterations too :@0.147059:0.865781:0.886416:0.865781:0.886416:0.845408:0.147059:0.845408:0.006209:0.011276:0.010934:0.005250:0.007670:0.003949:0.006211:0.011048:0.003949:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.003949:0.006620:0.011299:0.009039:0.007873:0.009039:0.003949:0.008765:0.011391:0.009085:0.011459:0.009656:0.009039:0.007670:0.003949:0.005615:0.011756:0.003949:0.007442:0.009291:0.009405:0.005250:0.007533:0.006437:0.005615:0.017485:0.009039:0.003949:0.009087:0.011596:0.011391:0.003949:0.006620:0.011094:0.011413:0.007670:0.003949:0.009656:0.009039:0.011596:0.009039:0.007898:0.009402:0.005387:0.005182:0.009724:0.003949:0.007442:0.009039:0.007510:0.011505:0.010843:0.011596:0.011391:0.003949:0.006209:0.011048:0.003949:0.009405:0.004908:0.006209:0.009039:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003949:0.006207:0.011276:0.011048:0.004109
late for true treatment success. We present a method to overcome these limitations and :@0.147059:0.886360:0.886551:0.886360:0.886551:0.865987:0.147059:0.865987:0.005433:0.008811:0.006209:0.009039:0.004908:0.006026:0.010843:0.007807:0.004908:0.006437:0.007964:0.011345:0.009039:0.004908:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004908:0.007510:0.011345:0.008994:0.008994:0.009039:0.007533:0.007670:0.004497:0.004908:0.018649:0.009039:0.004908:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.004908:0.009291:0.004908:0.017488:0.009128:0.006620:0.011302:0.011274:0.011391:0.004908:0.006209:0.011048:0.004908:0.010866:0.009633:0.009039:0.007442:0.008994:0.010843:0.017485:0.009039:0.004908:0.006620:0.011299:0.009039:0.007875:0.009039:0.004908:0.005250:0.005615:0.017645:0.005273:0.006549:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004908:0.009085:0.011596:0.011391:0.004109
provide a solution to immediate individualized disease monitoring. This approach could :@0.147059:0.906939:0.886416:0.906939:0.886416:0.886566:0.147059:0.886566:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.003629:0.009291:0.003629:0.007875:0.010934:0.004908:0.011071:0.006437:0.005547:0.010843:0.011756:0.003629:0.006209:0.011048:0.003629:0.005615:0.017645:0.017485:0.009108:0.011391:0.005798:0.008811:0.006209:0.009039:0.003629:0.005615:0.011596:0.011391:0.005547:0.009838:0.005547:0.011048:0.011596:0.009402:0.005250:0.005615:0.008834:0.009108:0.011391:0.003629:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.009039:0.003629:0.017485:0.010843:0.011756:0.005271:0.006211:0.010843:0.007807:0.005615:0.011461:0.009679:0.004497:0.003629:0.011470:0.011470:0.005615:0.007670:0.003629:0.008811:0.011046:0.011071:0.007444:0.011137:0.009291:0.008765:0.011459:0.003629:0.008994:0.010820:0.011550:0.005182:0.011391:0.004109